ERFA HYDROQUINONE 4 %
HYDROQUINONE : 4 % · DIN 02491702 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is ERFA HYDROQUINONE?
ERFA HYDROQUINONE 4 % contains HYDROQUINONE : 4 %. It is listed in the Health Canada Drug Product Database under DIN 02491702, held by SEARCHLIGHT PHARMA INC, supplied as GEL for TOPICAL administration. Health Canada currently lists it as marketed, status dated 29-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ERFA HYDROQUINONE used for?
Short-term treatment of hyperpigmented skin conditions: chloasma, melasma, liver spots, age spots, freckles, senile/solar lentigines, and post-inflammatory hyperpigmentation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02491702 |
|---|---|
| Brand name | ERFA HYDROQUINONE |
| Generic / active ingredient | HYDROQUINONE : 4 % |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 4 % |
| Dosage form | GEL |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D11AX11 HYDROQUINONE |
| AHFS class | 84:50.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Sep-2022 |
| Original market date | 2020-03-13 00:00:00 |
How is it administered?
Apply to affected areas and rub in well twice daily (morning and bedtime). Test for skin sensitivity before use. Discontinue if no improvement after 2 months (3 weeks for melasma).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15-30°C). Do not freeze. Keep tube sealed to protect from light. Do not use if dark coloration is observed.
How is it supplied?
30 g tube.
Contraindications
Hypersensitivity to hydroquinone or any ingredient. Safety during pregnancy or for children has not been studied.
Warnings and precautions
Risk of exogenous ochronosis and leukoderma with continuous use. Contains sulfites (allergic reactions) and AHAs (increased sun sensitivity). Use UV protection. Avoid contact with eyes.
What can be used instead?
Other Canadian products sharing ATC code D11AX11 HYDROQUINONE. 1 of 67 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACTIVE 4 | 4 % | CREAM | VIVIER CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02248851 |
| AFRICAN GOLD SKIN DISCOLORATION FADE CRM 2% | 2 % | CREAM | J. STRICKLAND & CO. | CANCELLED POST MARKET | DIN 02029227 |
| AMBI EXTRA SKIN DISCOLORATION FADE CREAM | 2 % | CREAM | KIWI BRANDS INC. | CANCELLED POST MARKET | DIN 02083337 |
| BANISHING CREAM | 2 % | CREAM | THE AVON COMPANY CANADA LIMITED | CANCELLED POST MARKET | DIN 00602736 |
| BLACK OPAL ADVANCE DUAL COMPLEX FADE GEL | 2 % | GEL | BIOCOSMETIC RESEARCH LABS DIVISION OF MANA PRODUCTS INC. | CANCELLED (UNRETURNED ANNUAL) | DIN 02240657 |
| BLACK OPAL ADVANCED DUAL PHASE FADE CREME | 2 % | CREAM | BIOCOSMETIC RESEARCH LABS DIVISION OF MANA PRODUCTS INC. | CANCELLED (UNRETURNED ANNUAL) | DIN 02240656 |
| CLAIRISSIME CLEAR COMPLEXION LOTION | 2 % | LOTION | AYOTAI CANADA INC. | CANCELLED POST MARKET | DIN 02251590 |
| CLEAR ESSENCE MEDICATED FADE CREAM | 2.5 % | CREAM | BLUEFIELD ASSOCIATES, INC. | CANCELLED (UNRETURNED ANNUAL) | DIN 02239114 |
| CLEAR-N-SMOOTH | 2 % | CREAM | HAWKNAD MANUFACTURING INDUSTRIES, INC. | CANCELLED (UNRETURNED ANNUAL) | DIN 02237828 |
| CONDITIONING GEL | 2 % | GEL | LABORATOIRES LA ROCHE-POSAY CANADA | CANCELLED POST MARKET | DIN 02237408 |
Who else supplies HYDROQUINONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROQUINONE appears in 23 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.